David A. Siegel Bicycle Therapeutics PLC Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 11,300 shares of BCYC stock, worth $165,997. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,300
Previous 30,900
63.43%
Holding current value
$165,997
Previous $625,000
59.04%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding BCYC
# of Institutions
111Shares Held
40.8MCall Options Held
39.6KPut Options Held
24.6K-
Baker Bros. Advisors LP New York, NY9.4MShares$138 Million2.28% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.55MShares$52.1 Million2.97% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.34MShares$34.4 Million9.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$33.1 Million0.71% of portfolio
-
Armistice Capital, LLC New York, NY1.96MShares$28.7 Million0.74% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $436M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...